Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog

By
A A A

Biogen Idec ( BIIB ) and partner AbbVie ( ABBV ) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab.

The global, randomized, double-blind, multicenter study was conducted to evaluate the superiority of daclizumab vis-à-vis Avonex, as a potential treatment for relapsing-remitting multiple sclerosis.

The results from the study showed that daclizumab was significantly superior and demonstrated a 45% reduction in ARR compared to Avonex. We note that the primary endpoint in the DECIDE study was the reduction in annualized relapse rate (ARR). On the other hand, although the safety profile of daclizumab in the study was consistent with what was observed in the prior studies, there was an increased incidence of serious infections, serious cutaneous reactions and elevations of liver transaminases in patients treated with daclizumab compared to Avonex.

Based on encouraging data from the study, both Biogen and AbbVie intend to work with regulatory agencies and determine appropriate timelines for filing. The full results from the DECIDE study will be presented at a conference later.

We note that Biogen holds a strong position in the multiple sclerosis (MS) market with drugs like Avonex, Tysabri and the recently launched oral MS treatment, Tecfidera. Tecfidera is off to a strong start in the U.S. and already holds a leading position in the oral MS market.

Meanwhile, Biogen is working on further strengthening its position in the MS market. The company has another candidate, Plegridy, in its pipeline, being evaluated for relapsing forms of MS.

Biogen recently received a boost when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion for Plegridy. 

We believe the successful development and approval of daclizumab and Plegridy will further strengthen its MS franchise.

Biogen is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the healthcare sector include companies like Gilead Sciences Inc. ( GILD ) and Allergan ( AGN ). Both carry a Zacks Rank #1 (Strong Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ARR , MS , CHMP , BIIB , ABBV

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,376
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com